🟢 Sakar Healthcare is trading 10.46% up today after 14 oncology approvals across three markets

Sakar Healthcare is trading 10.46% up now at ₹1120.00 after receiving 14 oncology-product approvals across the EU, UK and Canada.

• The September 1 announcement included five additional EMA site-variation approvals under its Accord Healthcare technology-transfer agreement.
• It also included six licensed-out product marketing authorisations, expanding coverage across multiple cancer treatments and strengthening Sakar’s regulated-market presence.
• The rally extends its recent advance, following an 11.86% gain on September 1 and further gains through September 4.